• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pre-Treatment Tumor Collagen is Associated with Triple-Negative Breast Cancer Pathological Response to Chemo-Immunotherapy.

作者信息

Jones Mackenzie, Alsafwani Zahraa W, Orozco Javier I J, Lele Subodh M, Nasser Mohd Wasim, Batra Surinder K, Santamaria-Barria Juan A

机构信息

Department of Surgery, University of Nebraska Medical Center, Omaha, NE, USA.

Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.

出版信息

Ann Surg Oncol. 2025 Jul 21. doi: 10.1245/s10434-025-17904-7.

DOI:10.1245/s10434-025-17904-7
PMID:40690171
Abstract
摘要

相似文献

1
Pre-Treatment Tumor Collagen is Associated with Triple-Negative Breast Cancer Pathological Response to Chemo-Immunotherapy.治疗前肿瘤胶原蛋白与三阴性乳腺癌对化学免疫疗法的病理反应相关。
Ann Surg Oncol. 2025 Jul 21. doi: 10.1245/s10434-025-17904-7.
2
Timing of Recurrence After Neoadjuvant Chemo-Immunotherapy in Early-Stage Triple-Negative Breast Cancer.早期三阴性乳腺癌新辅助化疗免疫治疗后的复发时间
Clin Cancer Res. 2025 Jul 21. doi: 10.1158/1078-0432.CCR-25-1478.
3
Co-delivery paclitaxel and IR783 as nanoparticles for potentiated chemo-photothermal-immunotherapy of triple-negative breast cancer.共递送紫杉醇和IR783作为纳米颗粒用于三阴性乳腺癌的增强化学-光热-免疫治疗。
Mater Today Bio. 2025 Jun 16;33:101993. doi: 10.1016/j.mtbio.2025.101993. eCollection 2025 Aug.
4
Multifunctional Nanoplatform for Highly Accurate Profiling of Triple-Negative Breast Cancer-Derived Chemo- and Immunotherapy Resistance Exosomes.用于高精度分析三阴性乳腺癌衍生的化疗和免疫治疗抗性外泌体的多功能纳米平台。
ACS Appl Bio Mater. 2025 Jul 21;8(7):5959-5969. doi: 10.1021/acsabm.5c00592. Epub 2025 Jun 17.
5
Sulindac sulfide as a non-immune suppressive γ-secretase modulator to target triple-negative breast cancer.硫化舒林作为一种非免疫抑制 γ-分泌酶调节剂，靶向三阴性乳腺癌。
Front Immunol. 2023 Oct 13;14:1244159. doi: 10.3389/fimmu.2023.1244159. eCollection 2023.
6
Adverse events in patients treated with neoadjuvant chemo/immunotherapy for triple negative breast cancer: results from seven academic medical centers.新辅助化疗/免疫治疗三阴乳腺癌患者的不良事件：来自七个学术医学中心的结果
Breast Cancer Res Treat. 2025 Jul 4. doi: 10.1007/s10549-025-07758-8.
7
Correlations of phosphorylated Nrf2 with responses to neoadjuvant chemotherapy in patients with triple-negative breast cancer.三阴性乳腺癌患者中磷酸化Nrf2与新辅助化疗反应的相关性。
BMC Womens Health. 2025 Jul 14;25(1):347. doi: 10.1186/s12905-025-03896-9.
8
Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment.依维莫司联合免疫检查点抑制剂治疗和化疗用于一线转移性三阴性乳腺癌可触发肿瘤微环境中巨噬细胞的重编程、免疫激活和细胞外基质重构。
J Immunother Cancer. 2024 Aug 30;12(8):e009160. doi: 10.1136/jitc-2024-009160.
9
Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.上皮细胞表达的 B7-H4 驱动了小鼠和人乳腺癌的免疫治疗反应差异。
Cancer Res Commun. 2024 Apr 24;4(4):1120-1134. doi: 10.1158/2767-9764.CRC-23-0468.
10
Efficacy and safety of neoadjuvant ICI combined with chemotherapy in breast cancer from the perspective of a privileged population: a systematic review and meta-analysis.从特殊人群角度看新辅助免疫检查点抑制剂联合化疗在乳腺癌中的疗效与安全性：一项系统评价与荟萃分析
Int J Surg. 2025 Jul 1;111(7):4726-4735. doi: 10.1097/JS9.0000000000002528. Epub 2025 May 26.

本文引用的文献

1
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.帕博利珠单抗治疗早期三阴性乳腺癌的总生存期。
N Engl J Med. 2024 Nov 28;391(21):1981-1991. doi: 10.1056/NEJMoa2409932. Epub 2024 Sep 15.
2
Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer: Prognostic and Predictive Significance across Molecular Subtypes.乳腺癌中的肿瘤浸润淋巴细胞（TILs）：跨分子亚型的预后和预测意义
Biomedicines. 2024 Mar 29;12(4):763. doi: 10.3390/biomedicines12040763.
3
Computational pathology identifies immune-mediated collagen disruption to predict clinical outcomes in gynecologic malignancies.
计算病理学识别免疫介导的胶原蛋白破坏以预测妇科恶性肿瘤的临床结果。
Commun Med (Lond). 2024 Jan 3;4(1):2. doi: 10.1038/s43856-023-00428-0.
4
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.重新定义乳腺癌亚型以指导治疗优先级排序并实现反应最大化：10 种癌症疗法的预测性生物标志物。
Cancer Cell. 2022 Jun 13;40(6):609-623.e6. doi: 10.1016/j.ccell.2022.05.005. Epub 2022 May 26.
5
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.度伐利尤单抗联合奥拉帕利和紫杉醇用于高风险 HER2 阴性 II/III 期乳腺癌：自适应随机化 I-SPY2 试验结果。
Cancer Cell. 2021 Jul 12;39(7):989-998.e5. doi: 10.1016/j.ccell.2021.05.009. Epub 2021 Jun 17.
6
Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression.肿瘤相关巨噬细胞驱动基质细胞依赖性胶原交联和变硬，促进乳腺癌侵袭。
Nat Mater. 2021 Apr;20(4):548-559. doi: 10.1038/s41563-020-00849-5. Epub 2020 Nov 30.
7
Pembrolizumab for Early Triple-Negative Breast Cancer.帕博利珠单抗治疗早期三阴性乳腺癌。
N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549.
8
Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration.人类乳腺癌的侵袭和侵袭性与细胞外基质硬化及免疫细胞浸润相关。
Integr Biol (Camb). 2015 Oct;7(10):1120-34. doi: 10.1039/c5ib00040h. Epub 2015 May 11.
9
Collagen density promotes mammary tumor initiation and progression.胶原蛋白密度促进乳腺肿瘤的起始和进展。
BMC Med. 2008 Apr 28;6:11. doi: 10.1186/1741-7015-6-11.